期刊
JOURNAL OF CLINICAL IMMUNOLOGY
卷 32, 期 5, 页码 936-941出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-012-9691-2
关键词
Acquired angioedema; C1-inhibitor deficiency, types I and II; anti-C1-inhibitor autoantibodies; rituximab
类别
Acquired C1-inhibitor deficiency can occur secondary to excessive C1-inhibitor consumption (type I) and be associated with a lymphoid hemopathy, or linked to the presence of anti-C1-inhibitor autoantibodies (type II) in a context of an isolated monoclonal gammopathy, sometimes associated with lymphoproliferation. Efficacy of danazol, tranexamic acid and/or corticosteroids is inconstant. Rituximab efficacy against type II angioedema has been reported. Description of 7 rituximab-treated patients, 6 with type II acquired angioedema and 1 with type I. Clinical efficacy (only for type II) was complete for 3, partial for 2 and 2 were therapeutic failures. Only 2 patients had improved biological parameters, with normalization of their C1-inhibitor levels and diminished anti-C1-inhibitor autoantibodies, observed 1-9 months after the last infusion of the second rituximab cycle. An associated lymphoproliferation did not affect the response to treatment. Rituximab efficacy in the treatment of acquired angioedema is inconstant and might require repeated cycles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据